ESPS-2 study

Introduction

multicenter, randomized, double-blind trial 6602 patients with a history of stroke or TIA primary endpoint: stroke or death at 2 years 4 treatment arms:

• aspirin 25 mg BID
• extended-release dipyridamole 200 mg BID
• Aggrenox BID
• placebo

Stroke-free survival at 24 months greatest in Aggrenox group (90%), aspirin group (87%), extended-release dipyridamole (87%), placebo (84%)

More general terms

• clinical trial